Evidence map›Paper›PMID 36355026›Full record

ArticleMarine drugs2022

Yingzi Wu, Yuanhui Li, Wenhai Guo, Jie Liu, Weiguo Lao, Penghui Hu, Yiguang Lin, Hongjie Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Yingzi WuDepartment of Traditional Chinese Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.ORCID 0000-0002-6174-0796
Yuanhui LiNational Marketing Center, Sinopharm Group Pharmaceutical Co., Ltd., Guangzhou 510010, China.
Wenhai GuoDepartment of Traditional Chinese Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Jie LiuState Key Laboratory of Respiratory Disease for Allergy and Shenzhen Key Laboratory of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen 518060, China.
Weiguo LaoDepartment of Biochemistry, Douglass Hanly Moir Pathology, Macquarie Park, NSW 2113, Australia.
Penghui HuDepartment of Oncology, Jiangmen Central Hospital, Jiangmen 529030, China.
Yiguang LinDepartment of Traditional Chinese Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.ORCID 0000-0002-4637-9701
Hongjie ChenDepartment of Traditional Chinese Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Sun Yat-sen University · CNChina National Pharmaceutical Group Corporation (China) · CNDouglass Hanly Moir Pathology · AUHong Kong Baptist University · HKJiangmen Central Hospital · CNShenzhen University · CNUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anticancer properties of

Indexed as

Carcinoma, HepatocellularLaminariaLiver NeoplasmsApoptosisCaspasesCell Line, TumorCell ProliferationHumansPeptidesPhosphatidylinositol 3-KinasesSignal TransductionCaspasesPeptidesPhosphatidylinositol 3-Kinasesapoptosiscancercell cycleLaminaria japonicaLaminaria japonica peptidesliverseaweed

Identifiers

PMID36355026
PMCPMC9698768
OpenAlexW4308869601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.